Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | CAR-T for elderly DLBCL

Frederick Locke • 2 Jun 2019
ASCO 2019
Diffuse Large B-Cell Lymphoma Axicabtagene ciloleucel
ZUMA-1

Frederick Locke, MD, of the Moffitt Cancer Center, Tampa, FL, discusses the treatment of elderly diffuse large B-cell lymphoma (DLBCL) with axicabtagene ciloleucel at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Frederick Locke

15:38
Highlights from Day 3: pushing the boundaries of CAR-T therapy in multiple myeloma & lymphoma
Frederick Locke et al. • 1 May 2022
3:52
Impact of age and co-morbidities on axi-cel efficacy
Frederick Locke • 29 Nov 2021
6:37
ZUMA-7: Axi-cel in r/r large B-cell lymphoma
Frederick Locke • 29 Nov 2021
1:15
The benefits of second-line CAR-T cell therapy
Frederick Locke • 29 Nov 2021

Related Videos

1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
2:09
Using lineage tracing to define responding CAR T-cells in patients with LBCL
Zinaida Good • 9 Apr 2024
4:34
Access to CAR-T in minority patients with lymphoma in the US: a retrospective analysis
Marco Ruella • 9 Apr 2024
1:30
Polatuzumab vedotin plus rituximab and lenalidomide in DLBCL: a Phase Ib/II study
Pau Abrisqueta • 5 Apr 2024
The content of VJHemOnc is intended for healthcare professionals